![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/crop/x_913,y_5,w_1980,h_1647/fill/w_438,h_364,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
.png){kind=logo}
Science & Applications
RESEARCH PAPERS
Journal of Neurology & Neuromedicine
January 2024
The Importance of Data Sources for Machine Learning Applications in Autism: A Mini Review
The mini-review extends beyond autism research, offering a glimpse into the potential of machine learning and pharmacometabolomics in a range of endocannabinoid system-related disorders.
​
![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/fill/w_600,h_440,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
Scientific Reports
August 2023
The paper showcases the potential of Cannformatics Cannabis-Responsive™ biomarker database to define the mechanism of action (MOA) and therapeutic window for every major cannabinoid.
​
Cannabinoid & Cannabis Research
March 2022
This paper demonstrates that Cannabis-Responsive biomarkers can provide life science companies and clinicians with new tools for understanding the role of cannabis in maintaining homeostasis of the central nervous system in children with ASD. This study also opens new opportunities to evaluate medical cannabis treatment in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS.
​
Cannabinoid & Cannabis Research
December 2021
The paper establishes Cannabis-Responsive biomarkers as a universal measurement of cannabis impact. The study positions medical cannabis as the only peer-reviewed published treatment to show a shift towards the physiological range in children with autism.
​
LETTERS TO THE EDITOR
Journal of Anesthesia & Analgesia
Cannabis-Responsive Biomarkers: Answering the Call for Critical Appraisal of Medical Cannabis
The Letter to the Editor is in response to an editorial the journal published titled, "Cannabis as a Therapeutic or Snake Oil? A Desperate Call for Critical Appraisal of the Literature." In our letter we outline how Cannabis-Responsive biomarkers replaces subjective evaluation with a pharmacometabolomics-based approach which show the metabolic benefits of medical cannabis treatment in children with autism spectrum disorder.​
